biolog
respons
modifi
brm
endogen
ie
natur
produc
bodi
exogen
administ
togeth
drug
agent
modul
immun
brm
regul
among
other
type
durat
intens
immun
respons
character
pleiotropi
redund
thymic
polypeptid
prothymosin
alpha
incorpor
larg
famili
brm
mainli
modul
effect
sever
properti
immun
effector
wide
distribut
cell
tissu
organ
broad
phylogenet
dissemin
lack
mechan
support
secret
question
initi
character
thymic
hormon
wide
acknowledg
possess
essenti
intracellular
role
relat
cell
surviv
growth
time
extracellularli
enhanc
function
divers
subpopul
immun
system
sever
novel
function
beyond
immunomodul
also
ascrib
accumul
data
suggest
immunopotenti
activ
could
therapeut
exploit
variou
clinic
condit
associ
immunodefici
immunosenesc
cancer
autoimmun
diseas
herein
present
promin
effect
polypeptid
report
variou
research
team
year
propos
compil
scenario
mode
action
provid
mean
eventu
could
lead
incorpor
clinic
trial
immunostimulantadjuv
thymu
remain
enigmat
organ
centuri
clinic
signific
true
function
much
disput
although
lymphopoiet
role
repeatedli
demonstr
miller
longprevail
opinion
claim
thymu
redund
organ
immunolog
function
earli
miller
good
colleagu
tip
balanc
favor
crucial
central
role
thymu
establish
compet
immun
system
good
et
al
miller
first
show
neonat
thymectom
mice
exhibit
mark
defici
lymphocyt
impair
immun
respons
associ
inabl
resist
infect
reject
histoincompat
transplant
howev
even
studi
could
fulli
elucid
exact
mechan
underli
continu
thymic
control
lymphocyt
function
year
later
unequivoc
proven
thymu
actual
gland
mediat
function
least
partial
humor
messag
mere
via
cellular
interact
aisenberg
wilk
levey
trainin
law
year
follow
goldstein
colleagu
isol
identifi
seri
hormonallik
agent
immunerestor
capac
goldstein
initi
effort
led
isol
partial
purifi
thymic
extract
could
enhanc
vivo
incorpor
tritiat
thymidin
dna
mous
lymph
node
indic
increas
lymphocyt
prolifer
klein
goldstein
white
invalu
aid
newli
develop
vitro
prolifer
assay
solubl
factor
induc
lymphocytopoiesi
purifi
character
name
thymosin
goldstein
slater
white
howev
major
breakthrough
isol
thymosin
fraction
v
tfv
purifi
prepar
immunoregulatori
activ
use
novel
complex
process
enabl
purif
larg
amount
hooper
et
al
tfv
properti
activ
explor
sever
vitro
vivo
studi
vitro
tfv
shown
stimul
lymphocyt
deriv
immunosuppress
human
restor
function
normal
level
wara
ammann
addit
tfv
enhanc
murin
spleen
cell
respons
mix
lymphocyt
reaction
mlr
mix
lymphocytetumor
cultur
mltc
talmadg
uithoven
lenz
chirigo
vivo
tfv
increas
surviv
neonat
thymectom
mice
spangelo
hall
goldstein
restor
graftvshost
reactiv
spangelo
et
al
correct
tcell
abnorm
mice
autoimmun
diseas
dauphine
tala
goldstein
white
interestingli
tfv
also
possess
direct
antiprolif
properti
malign
cell
demonstr
vitro
murin
pituitari
adenocarcinoma
glioma
spangelo
farrimond
pompiliu
bowman
human
acut
lymphoblast
ho
price
hunstein
hovbrand
promyelocyt
leukemia
cell
line
spangelo
et
al
final
vivo
treatment
tfv
confer
resist
dun
khaw
rule
murin
lymphoblast
leukemia
petro
watson
immunestimul
restor
activ
attribut
tfv
trigger
need
identifi
sever
compon
thorough
fraction
analysi
reveal
tfv
consist
least
differ
molecul
princip
secondari
compon
major
molecul
acid
vari
molecular
weight
da
nomenclatur
system
base
upon
isoelectr
point
pi
peptid
result
tfv
subdivis
three
differ
group
one
identifi
greek
letter
ie
alpha
beta
gamma
thu
peptid
pi
less
name
pi
term
peptid
pi
greater
consid
subscript
number
use
identifi
peptid
group
indic
order
isol
tfv
eg
etc
goldstein
first
two
peptid
identifi
fulli
character
thymosin
goldstein
et
al
thymosin
low
hu
goldstein
immunopotenti
properti
extens
studi
year
follow
spangelo
et
al
subsequ
number
isol
sequenc
thymu
tissu
hannappel
huff
util
newli
develop
method
reduc
effect
proteolysi
peptid
isol
hannappel
colleagu
demonstr
major
compon
calf
thymu
extract
absent
present
trace
amount
hannappel
davoust
horeck
latter
observ
led
investig
hypothes
presenc
tfv
result
proteolyt
cleavag
precursor
peptid
specul
fuel
evid
show
previous
isol
peptid
actual
proteolyt
product
longer
molecul
hannappel
davoust
horeck
addit
group
isol
two
peptid
tfv
whose
sequenc
strongli
resembl
compar
one
peptid
lack
four
amino
acid
carboxi
c
terminu
therefor
name
de
second
addit
seven
amino
acid
cterminu
given
name
caldarella
et
al
consequ
search
larger
precursor
molecul
began
effort
isol
nativ
polypeptid
harito
colleagu
develop
radioimmunoassay
base
antibodi
rais
synthet
harito
horeck
coupl
assay
isol
procedur
design
minim
proteolyt
activ
cell
extract
eventu
isol
initi
rat
thymu
polypeptid
amino
acid
long
contain
sequenc
amino
acid
residu
amino
n
terminu
harito
goodal
horeck
name
polypeptid
indic
sourc
relat
peptid
fragment
present
tfv
prepar
human
amino
acid
long
encod
ptma
gene
locat
chromosom
szabo
et
al
nearli
half
total
residu
account
glutam
aspart
acid
result
molecul
acquir
particularli
low
pi
although
initi
refer
thymic
hormon
sole
express
thymu
detect
tissu
harito
tsola
horeck
notic
conserv
polypeptid
character
high
degre
sequenc
homolog
among
mammal
hannappel
huff
overexpress
cell
increas
physiolog
eg
young
thymu
abnorm
eg
malign
prolif
capac
harito
acid
residu
found
primarili
within
central
segment
polypeptid
chain
molecul
specif
secondari
structur
eventu
adopt
random
coil
conform
gast
et
al
howev
possibl
acquir
secondari
structur
upon
interact
protein
rule
cordero
nogueira
support
demonstr
specif
condit
low
ph
high
concentr
polypeptid
form
amyloid
fibril
pavlov
cherni
heim
jovin
subramaniam
although
releas
necrot
neuron
via
uniqu
nonclass
pathway
halder
matsunaga
ueda
matsunaga
ueda
peptid
lack
signal
peptid
sequenc
requir
secret
instead
bear
bipartit
nuclear
local
signal
consist
two
block
basic
residu
kr
tkkqkt
necessari
suffici
import
protein
nucleu
predominantli
locat
manrow
sburlati
hanov
berger
rubtsov
et
al
contradict
mani
studi
also
support
cytoplasm
local
sburlati
manrow
berger
tsitsiloni
yialouri
sekeripatarya
harito
effort
address
antiphasi
enkemann
cowork
demonstr
principl
detect
activ
transcript
site
nucleu
smaller
fraction
remain
cytoplasm
enkemann
wang
trumbor
berger
addit
suggest
owe
small
size
neg
charg
may
facilit
movement
posit
charg
molecul
eg
histon
within
nucleu
particularli
highli
charg
environ
need
overcom
electrostat
interact
term
biolog
role
vast
number
studi
attribut
among
other
variou
divers
immunerel
properti
polypeptid
import
analyz
later
potent
anticanc
activ
studi
earli
first
report
regul
mhc
class
ii
express
human
mous
antigenpres
cell
apc
baxevani
et
al
signific
observ
verifi
three
serial
studi
leukem
vivo
anim
model
mice
inocul
cell
therapeut
treat
surviv
month
papanastasi
baxevani
papamichail
immunolog
modif
caus
includ
vivo
gener
mhcrestrict
tumorspecif
cytotox
lymphocyt
ctl
baxevani
gritzapi
spanako
tsitsiloni
papamichail
concomitantli
enhanc
tumorreact
nk
cellmedi
cytotox
baxevani
et
al
effector
effici
lyse
syngen
tumor
cell
immunoenhanc
effect
exert
upstream
lymphocyt
activ
via
interleukin
il
manner
importantli
shift
antitumorreact
immun
respons
toward
stimul
suitabl
effector
ctl
nk
cell
depend
presenc
absenc
tumorspecif
antigen
peptid
respect
anim
studi
follow
vitro
human
studi
lymphocyt
cancer
patient
cancer
induc
sever
immun
dysfunct
intensifi
anticanc
therapi
administ
patient
shown
restor
defici
peripher
blood
lymphocyt
deriv
patient
advanc
solid
tumor
enhanc
allogen
cellmedi
lympholysi
antigen
present
confirm
increas
valu
record
mlr
reduc
nk
tcell
cytotox
activ
regul
level
prostaglandin
baxevani
reclo
papamichail
two
consecut
studi
melanoma
colon
cancer
patient
show
could
act
benefici
earlystag
cancer
combin
lowdos
interferon
ifn
significantli
enhanc
monocyt
nk
lak
cell
tumoristat
tumorilyt
activ
garbin
eckert
uttner
garb
maurer
conjunct
either
increas
adhes
monocyt
tumor
target
express
characterist
nk
cell
marker
eg
enhanc
lytic
activ
lak
cell
particular
inhibit
secret
induc
product
secret
high
level
proinflammatori
cytokin
tumor
necrosi
factor
tnf
cordero
sarandes
nogueira
eckert
unberg
garbin
maurer
eckert
unberg
immenschuh
et
al
garbin
eckert
immenschuh
kreuser
maurer
cordero
sarandes
nogueira
base
aforement
data
first
mean
action
shape
indic
polypeptid
restor
cancer
patient
lymphocyt
defici
select
control
function
monocyt
monocyt
turn
produc
cytokin
gener
favor
cytokin
milieu
facilit
lymphocyt
activ
optim
effect
synergi
low
concentr
brm
assess
exampl
combin
monoclon
antibodi
synergi
increas
tumor
celllysi
mhcand
nonmhcrestrict
pbmc
effector
baxevani
et
al
result
complement
eleg
studi
voutsa
et
al
use
mltc
synergi
lowdos
led
expans
tumorreact
cell
subsequ
gener
mhc
class
irestrict
autolog
tumorspecif
ctl
first
studi
show
order
fulli
exert
benefici
effect
ctl
concomit
presenc
autolog
cell
monocyt
requir
combin
previou
data
attempt
fill
gap
research
team
use
proteom
elucid
mechan
action
healthi
donorand
cancer
patientderiv
pbmc
base
protein
upand
downregul
upon
pbmc
treatment
first
analyt
describ
scenario
underli
immunoenhanc
activ
suggest
ligat
innat
immun
receptor
apc
lead
format
strong
apctcel
synaps
proinflammatori
cytokin
secret
thu
indirect
increas
cytotox
ctl
nk
cell
effector
skopel
et
al
other
confirm
realism
scenario
show
ligat
tolllik
receptor
mosoian
et
al
omotuyi
matsunaga
ueda
matur
monocytederiv
dendrit
cell
dc
express
costimulatori
molecul
skopel
et
al
secret
proinflammatori
cytokin
moreov
dc
load
tumor
antigen
induc
polar
h
tumorreact
immun
respons
result
gener
polyfunct
highli
lytic
tumor
antigenspecif
ctl
besid
dc
could
also
activ
immun
cell
type
express
eg
neutrophil
secret
kill
tumor
cell
vitro
macrophag
mosoian
et
al
ex
vivo
experi
show
significantli
restor
reduc
cytotox
immunosuppress
ascitesderiv
tumorassoci
lymphocyt
ovarian
tumor
cell
inhibit
ovarian
tumor
growth
scid
mice
inocul
human
tumor
voutsa
et
al
control
viral
replic
human
requir
involv
robust
ctl
respons
turn
demand
presenc
type
ifn
support
tcell
develop
function
welsh
bahl
marshal
urban
interestingli
shown
regul
enhanc
type
ifn
secret
antivir
properti
investig
qiu
colleagu
provid
first
evid
capac
enhanc
secret
murin
macrophag
qiu
et
al
later
proteom
analysi
human
mononuclear
cell
treat
reveal
polypeptid
enhanc
express
mixovirusresist
protein
protein
possess
signific
antivir
activ
skopel
et
al
moreov
identifi
potent
suppressor
human
immunodefici
viru
hiv
replic
primari
macrophag
releas
virusinfect
cell
also
shown
inhibit
occur
follow
viral
integr
viru
specif
mosoian
et
al
rather
mediat
upregul
type
ifn
follow
activ
mosoian
et
al
teixeira
et
al
similarli
releas
upon
infect
guinea
pig
attenu
strain
pichind
viru
led
induct
potent
antivir
immun
consequ
viral
clearanc
bowick
et
al
term
vivo
applic
use
potent
adjuv
hepat
b
viru
dna
vaccin
success
enhanc
humor
cellular
immun
respons
jin
et
al
impress
recent
report
show
display
antivir
activ
class
mammal
specif
fish
tongu
sole
infect
megalocytiviru
zhang
sun
neuron
death
induc
stroke
trauma
occur
via
necrosi
apoptosi
apoptosi
regul
process
limit
damag
brain
necrosi
tend
expand
therefor
target
stroke
treatment
ueda
base
premis
effort
identifi
solubl
molecul
could
inhibit
necrosi
ueda
colleagu
isol
identifi
uniqu
antineuron
necrosi
factor
condit
medium
cortic
neuron
ueda
fujita
yoshida
matsunaga
ueda
detail
could
revers
rapid
decreas
surviv
cortic
neuron
abolish
typic
necrosi
featur
cell
switch
cell
death
mode
necrosi
apoptosi
later
potent
neuroprotect
function
also
demonstr
vivo
experiment
induc
cerebr
retin
ischemia
fujita
ueda
fujiwara
ueda
mechan
underli
neuroprotect
role
shown
polypeptid
releas
via
nonclass
manner
ischem
stress
condit
extracellular
releas
facilit
interact
cargo
molecul
name
halder
et
al
matsunaga
ueda
upon
releas
activ
pathway
induc
express
neuroprotect
factor
halder
matsunaga
ishii
ueda
given
neuroprotect
properti
effect
cardiomyocyt
ischem
injuri
also
investig
cannavo
et
al
vitro
treatment
cardiomyocyt
recombin
simul
ischemia
significantli
decreas
apoptot
respons
enhanc
cell
surviv
consist
vitro
find
vivo
administr
follow
myocardi
infarct
success
reduc
infarct
size
mice
compar
untreat
control
effect
mediat
aktdepend
mechan
li
colleagu
initi
report
transgen
mice
exhibit
polycyst
kidney
diseas
phenotyp
well
emphysemalik
chang
lung
li
shiau
chiou
yo
wu
studi
research
group
show
enhanc
acetyl
histon
nuclear
factorkappa
b
inhibit
smad
signal
thu
contribut
develop
emphysema
su
et
al
su
et
al
furthermor
high
level
posit
correl
sever
emphysema
transgen
mice
emphysema
patient
su
et
al
final
polypeptid
involv
induct
insulin
resist
investig
reportedli
regul
inflammatori
respons
oxid
stress
featur
associ
diabet
su
et
al
patient
type
diabet
significantli
higher
level
serum
compar
normal
individu
transgen
mice
exhibit
insulinresist
phenotyp
exploit
underli
mechan
reveal
induc
insulin
resist
pathway
sinc
first
thymosin
isol
identifi
tfv
natur
precursor
smaller
harito
goodal
et
al
initi
consid
major
immunoact
fragment
polypeptid
howev
data
accru
particular
last
year
reveal
exert
immunomodul
role
divers
fragment
ctermin
fragment
span
residu
skopel
et
al
central
neg
charg
region
mosoian
et
al
two
point
consid
import
compar
fragment
intact
seem
perform
better
least
immunebas
assay
differ
area
molecul
seem
respons
divers
activ
tabl
cardioprotect
cannavo
et
al
acidlong
ntermin
fragment
report
enhanc
human
cellmedi
immun
stimul
endotheli
cell
migrat
angiogenesi
wound
heal
malinda
et
al
test
man
use
broad
rang
clinic
applic
singl
agent
combin
standard
treatment
eg
chemotherapeut
show
excel
safeti
profil
romani
et
al
among
clinic
case
use
treat
infecti
diseas
includ
viral
chronic
hepat
b
c
aid
fungal
aspergillosi
bone
marrowtranspl
patient
bacteri
pseudomona
aeruginosa
sepsi
sever
lung
patholog
eg
chronic
obstruct
pulmonari
diseas
acut
respiratori
distress
syndrom
sever
acut
respiratori
syndrom
agerel
defici
cancer
vaccin
enhanc
camerini
garaci
howev
despit
promis
data
gener
far
clinic
benefit
administr
specif
patholog
still
disput
need
verifi
larger
welldesign
random
clinic
trial
ctermin
decapeptid
tkkqktdedd
identifi
research
team
immunoact
area
polypeptid
potent
lymphocyt
stimul
skopel
et
al
shown
stimul
pbmc
prolifer
cytotox
promot
phenotyp
matur
dc
skopel
et
al
consequ
improv
function
immunogen
peptidepuls
dc
induc
h
immun
respons
polar
augment
basic
properti
human
neutrophil
enhanc
depress
cytotox
tumorassoci
lymphocyt
autolog
tumor
cell
vitro
retard
tumor
growth
vivo
voutsa
et
al
use
control
scrambl
decapeptid
amino
acid
composit
differ
primari
structur
immunoenhanc
activ
shown
sequencespecif
compar
intact
recent
report
radiolabel
tc
bind
surfac
human
neutrophil
via
complex
involv
karachali
et
al
select
accumul
site
experiment
induc
inflamm
ce
karachali
et
al
person
commun
base
fact
decapeptid
vivo
gener
upon
caspas
cleavag
apoptosi
enkemann
et
al
evstafieva
et
al
develop
highli
sensit
specif
competit
elisa
use
high
affinitypurifi
polyclon
antibodi
decapeptid
quantifi
serum
healthi
human
detect
low
concentr
ngml
p
samara
et
al
unpublish
data
wherea
higher
level
record
serum
mice
infect
bacterium
streptococcu
pyogen
suggest
correl
level
progress
bacteri
infect
two
ctermin
immunomodulatori
peptid
fragment
report
earlier
studi
research
group
identifi
slightli
smaller
segment
name
also
effect
vitro
restor
immun
function
pbmc
deriv
cancer
patient
skopel
et
al
recent
gravimetr
assay
molecular
dynam
simul
reveal
via
ctermin
segment
similar
lp
biophys
interact
vitro
complex
overlap
lpsbind
posit
omotuyi
et
al
research
group
mosoian
introduc
synthet
peptid
span
amino
acid
design
attempt
comprehend
mediat
activ
induc
type
ifn
product
incub
human
macrophag
myeloid
dc
stimul
product
shown
increas
type
ifn
mrna
mosoian
et
al
furthermor
research
team
recent
report
variant
isob
span
middl
segment
sequenc
polypeptid
amino
acid
also
induc
mrna
express
type
type
iii
ifn
human
macrophag
suggest
peptid
possess
strong
antivir
activ
respons
regist
suppress
replic
cell
type
teixeira
et
al
addit
ueda
colleagu
report
acid
middl
peptid
sequenc
term
exert
substanti
neuroprotect
activ
vitro
vivo
inhibit
cerebr
blood
vessel
damag
caus
ischem
stress
retina
brain
minimum
neuroprotect
sequenc
encompass
acid
peptid
shown
compris
full
neuroprotect
effect
cultur
cortic
neuron
ischem
condit
halder
et
al
long
disput
whether
strictli
intracellular
principl
nuclear
molecul
like
could
modul
immun
respons
sever
research
initi
reject
idea
polypeptid
could
exert
extracellular
role
wide
distribut
tissu
cell
strongli
support
sole
implic
polypeptid
crucial
intracellular
process
inde
normal
cell
shown
import
surviv
prolifer
high
level
mrna
detect
lymphocyt
eschenfeldt
berger
szabo
ehleit
whittington
weksler
cell
stimul
divid
wu
shiau
lin
wherea
prolifer
myeloma
cell
hinder
presenc
antisens
oligom
year
research
intracellular
activ
reveal
implic
gene
transcript
report
local
nuclear
site
activ
transcript
physic
interact
crebbind
protein
cbp
bind
histon
stimul
transcript
karets
kretsovali
murphi
tsola
papamarcaki
dna
remodel
prolifer
increas
access
micrococc
nucleas
chromatin
gomezmarquez
rodriguez
inhibit
apoptosi
shown
bind
inhibit
apoptosom
format
jiang
et
al
protect
oxid
stress
interact
lead
nuclear
transloc
mediat
degrad
promot
cell
surviv
growth
nitur
kaspar
shen
jaiswal
fig
cancer
cell
highli
prolif
divid
constantli
increas
content
also
report
high
level
detect
human
colon
mori
et
al
colorect
zhang
et
al
lung
sasaki
nonaka
et
al
bladder
tsai
et
al
liver
cancer
wu
habib
et
al
neuroblastoma
sasaki
sato
et
al
rhabdomyosarcoma
carey
et
al
thyroid
carcinoma
kashat
et
al
letsa
vartholomato
tsepi
tsatsouli
frangoulazaridi
pituitari
tumor
pawlikowski
et
al
head
neck
cancer
tripathi
et
al
gastric
adenocarcinoma
ley
et
al
hepatocellular
ha
song
hwang
cho
park
urinari
tract
transit
cell
carcinoma
jou
et
al
other
report
elev
breast
tumor
tsitsiloni
et
al
tumor
level
correl
diseas
outcom
dominguez
et
al
fig
intracellular
role
absenc
histon
bind
nucleosom
induc
condens
euchromatin
heterochromatin
interact
histon
mediat
transfer
chromatin
lead
format
complex
chromatin
remodel
gene
transcript
b
apoptot
stimuli
induc
releas
cytochrom
c
bind
form
apoptosom
subsequ
activ
caspas
result
convers
procaspas
caspas
lead
apoptosi
hinder
bind
cytochrom
c
apoptot
cascad
inhibit
c
normal
complex
ubiquitin
degrad
proteasom
oxid
stress
bind
complex
via
releas
migrat
nucleu
promot
gene
transcript
antioxid
enzym
product
metastat
potenti
tumor
tsitsiloni
et
al
risk
recurr
death
magdalena
dominguez
loidi
puent
worth
mention
high
level
detect
prostat
cancer
sampl
klimentz
et
al
shown
progress
increas
prostat
tissu
progress
normal
epithelium
prostat
intraepitheli
neoplasia
carcinoma
correl
gleason
score
suzuki
et
al
therefor
follow
appropri
valid
tumor
content
andor
serum
level
may
use
surrog
tumor
biomark
cancer
develop
prognosi
followup
nevertheless
evid
support
extracellular
activ
also
report
vivo
studi
anim
show
protect
mice
opportunist
infect
particular
candida
albican
pan
et
al
numer
vitro
studi
confirm
extracellular
role
polypeptid
alreadi
aforement
peripher
blood
cell
stimul
produc
high
amount
increas
express
receptor
surfac
baxevani
et
al
cordero
et
al
apc
dc
activ
upregul
mhc
class
ii
costimulatori
molecul
skopel
et
al
respect
nk
lak
cell
cultur
presenc
augment
cytotox
cordero
sarandes
nogueira
et
al
neutrophil
show
increas
chemotaxi
produc
high
amount
ro
becam
cytotox
cancer
cell
target
heideck
eckert
schulzeforst
maurer
multipl
immunolog
respons
suggest
act
pleiotrop
especi
immunosuppress
environ
time
obviou
cytokinelik
activ
would
justifi
specificbind
site
receptor
immun
cell
surfac
discov
initi
attempt
cordero
colleagu
radiolabel
search
bind
site
surfac
lymphoblast
two
bind
site
low
high
affin
identifi
cordero
sarandes
nogueira
five
year
later
research
demonstr
affin
crosslink
chromatographi
exist
three
bind
partner
membran
phaactiv
lymphoblast
associ
lipid
raft
bugia
pilar
aria
cordero
nogueira
salgado
lojo
nogueira
howev
specif
receptor
never
clone
base
detail
proteom
analysi
protein
chang
induc
immun
cell
upregul
signal
protein
propos
ligat
tlr
skopel
et
al
mosoian
colleagu
confirm
ligat
signal
trifdepend
pathway
induct
proinflammatori
cytokin
respect
mosoian
et
al
recent
shown
bind
complex
activ
pathway
downstream
halder
et
al
omotuyi
et
al
although
data
need
gener
specif
defin
pathway
activ
respons
tempt
specul
polypeptid
probabl
belong
vagu
famili
molecul
term
damageassoci
molecular
pattern
damp
els
alarmin
bianchi
simultan
distinct
exert
intracellular
extracellular
role
term
alarmin
practic
refer
endogen
pathogenassoci
molecular
pattern
pamp
detail
multifunct
endogen
constitut
avail
molecul
passiv
releas
damag
cell
rapidli
secret
stimul
leukocyt
epitheli
cell
follow
tissu
destruct
alarmin
activ
innat
adapt
immun
respons
uncontrol
excess
releas
alarmin
extracellularli
induc
concomitantli
recruit
activ
apc
pattern
recognit
receptor
tlr
absenc
stimuli
alarmin
exert
vital
intracellular
role
alarmin
famili
rapidli
grow
bestcharacter
member
highmobl
group
protein
heatshock
protein
bianchi
thymosin
suggest
candid
alarmin
although
knowledg
direct
comparison
characterist
known
alarmin
perform
herein
compil
evid
possess
sever
attribut
consid
alarmin
tabl
among
other
comparison
ubiquit
express
nonhiston
nuclear
protein
mark
intracellular
physiolog
role
regul
transcript
releas
via
nonclass
pathway
upon
ischem
stress
local
extracellularli
recruit
activ
innat
immun
cell
promot
inflamm
cytokin
secret
similar
addit
signal
activ
leukocyt
orchestr
immun
respons
ioannou
et
al
final
implic
neuroand
cardiotissu
repair
suggest
regen
potenti
polypeptid
cannavo
et
al
halder
et
al
chan
et
al
schiller
et
al
telusma
et
al
cannavo
et
al
halder
et
al
ioannou
samara
livani
derhovanessian
tsitsiloni
origin
nonhiston
nuclear
protein
nonhiston
nuclear
protein
take
consider
propos
scenario
depict
mode
action
normal
healthi
cell
local
nucleu
eschenfeldt
berger
albeit
fraction
assign
remain
cytoplasm
tsitsiloni
et
al
nucleu
regul
gene
transcript
karets
et
al
shape
dna
remodel
promot
cell
prolifer
gomezmarquez
rodriguez
cytoplasm
protect
cell
apoptosi
jiang
et
al
due
neg
charg
facilit
transport
molecul
nucleu
protect
cell
insult
eg
oxid
stress
nitur
et
al
hyperprolif
cell
like
cancer
cell
gene
express
protein
content
increas
contribut
uncontrol
prolifer
induct
resist
apoptosi
oxid
stress
cell
receiv
death
stimuli
die
violent
necrosi
undergo
program
apoptot
death
necrosi
cell
swell
membran
disrupt
lead
abrupt
uncontrol
releas
intern
cell
compon
includ
act
alarmin
alert
cell
innat
arm
immun
express
initi
immun
respons
ioannou
et
al
apoptosi
major
proport
transfer
cytoplasm
activ
caspas
cleav
molecul
cterminu
gener
among
fragment
decapeptid
neg
charg
fragment
remain
cytoplasm
probabl
degrad
suggest
expos
apoptot
cell
surfac
act
eatm
signal
evstafieva
et
al
decapeptid
proport
protect
degrad
polymer
adopt
conform
skopel
et
al
consequ
excret
die
cell
via
unknown
mechan
necrosi
apoptosi
exocytos
sens
damp
innat
immun
cell
ligat
mosoian
et
al
stimul
innat
immun
cell
macrophag
neutrophil
monocyt
dc
respond
initi
molecular
signal
pathway
lead
activ
chemokin
ifn
proinflammatori
cytokin
secret
addit
stimul
macrophag
neutrophil
increas
phagocytosi
produc
respect
mosoian
et
al
stimul
apc
dc
monocyt
increas
antigen
eg
shed
die
cancer
cell
uptak
present
mhc
class
molecul
directli
cytotox
cell
upregul
mhc
class
ii
express
thymic
peptid
monocyt
dc
increas
antigen
present
synaps
helper
cell
produc
h
cytokin
eg
provid
favor
environ
enhanc
specif
fig
propos
scenario
dual
role
normal
cell
regul
gene
express
cell
prolifer
nucleu
abnorm
condit
cell
die
via
necrosi
apoptosi
necrosi
cell
membran
ruptur
intact
releas
cell
apoptosi
reloc
cytoplasm
cleav
cterminu
activ
caspas
gener
decapeptid
adopt
conform
excret
extracellularli
activ
innat
immun
cell
express
macrophag
neutrophil
dc
monocyt
signal
trif
pathway
cytotox
respons
enhanc
antigen
present
mhc
class
ii
molecul
synapsi
helper
cell
secret
h
cytokin
andor
mhc
class
molecul
lead
activ
cytotox
effector
nk
cell
ctl
case
effector
cell
upregul
adhes
molecul
express
eg
produc
lytic
molecul
eg
perforin
mediat
cell
bind
cell
destruct
respect
eg
cancer
cell
target
shown
nonspecif
cytotox
ctl
nk
cell
produc
lytic
molecul
perforin
express
adhes
molecul
secret
kill
cell
target
eg
cancer
cell
fig
although
initi
character
thymic
hormon
ubiquit
express
polypeptid
exert
pleiotrop
immunostimulatori
adjuv
effect
nevertheless
despit
extens
intens
research
mode
action
efficaci
yet
test
human
opinion
main
reason
stand
lack
understand
dual
role
elucid
molecul
promot
cell
prolifer
mediat
immun
paradox
surpris
contradictori
case
cancer
know
increas
gene
transcript
correl
carcinogenesi
wherea
ligat
promot
anticancerreact
immun
respons
view
recent
progress
elucid
complex
machineri
immun
respons
concept
immun
system
respond
pathogen
pamp
danger
signal
damp
adjuv
mode
action
point
toward
integr
famili
alarmin
specif
condit
relat
danger
result
cell
damag
destruct
death
andor
smaller
fragment
molecul
eg
reloc
extracellularli
ie
differ
site
insid
cell
physiolog
function
innat
immun
cell
like
dc
program
sens
danger
respond
cascad
immun
respons
initi
recent
evid
addit
suggest
tlr
agonist
present
drive
closer
optim
orchestr
immun
machineri
sever
tlr
agonist
reach
clinic
set
believ
adequ
proven
potent
immunostimul
capac
vitro
anim
vivo
gener
appropri
cytokin
milieu
promot
activ
effector
cell
although
studi
detail
also
known
polypeptid
administ
anim
rel
high
concentr
induc
toxic
sever
advers
effect
therefor
next
step
test
adjuv
effect
smaller
immunoact
fragment
thereof
clinic
studi
aim
strengthen
defici
immun
respons
